Cargando…

Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Papadopoulos, Christodoulos, Katsimardou, Alexandra, Toumpourleka, Maria, Doumas, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556544/ https://www.ncbi.nlm.nih.gov/pubmed/33052538 http://dx.doi.org/10.1007/s13300-020-00942-7

Ejemplares similares

Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
por: Bossi, Antonio C., et al.
Publicado: (2020)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review
por: Papadopoulos, Christodoulos, et al.
Publicado: (2020)

Colchicine for the prevention of COVID-19 “hard” outcomes: All that glitters is not gold
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

COVID-19: The Waterloo of governments, healthcare systems, and large health organizations
por: Doumas, Michael, et al.
Publicado: (2020)

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
por: Doumas, Michael, et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?
por: Patoulias, Dimitrios
Publicado: (2023)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Perioperative Implication of Sodium-glucose Cotransporter-2 Inhibitor in a Patient Following Major Surgery
por: Vadi, Sonali, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_22vgpmd5donp1nnojt8ll92lej